Equipe Zorgbedrijven Nederland B.V.
- Address
- Flight Forum 130, 5657 DD Eindhoven, The Netherlands
Analytical, Diagnostic and Therapeutic Techniques and Equipment – Anesthesia and Analgesia
The research program concentrates on advanced anesthesia and pain‑relief methods for patients undergoing joint replacement surgery, aiming to improve comfort and reduce reliance on rescue medication.
- Preoperative intra‑articular infiltration of the hip joint
- Optimization of postoperative analgesia protocols
- Evaluation of novel local anesthetic combinations
A key study investigates whether a targeted injection of ropivacaine and adrenaline before surgery can lower the need for additional pain medication after total hip arthroplasty.
Cardiovascular Diseases
This area explores strategies to prevent blood clots in patients receiving hip or knee replacements, focusing on personalized anticoagulation to balance efficacy and safety.
- Individualized thrombosis prophylaxis based on patient risk
- Comparison of standard versus intensified anticoagulant regimens
- Assessment of bleeding complications alongside clot prevention
Researchers at Equipe Zorgbedrijven Nederland B.V. aim to identify the optimal approach to protect against venous thromboembolism while minimizing adverse bleeding events.
Musculoskeletal Diseases
The focus here is on outcomes of joint replacement procedures, particularly the occurrence of clotting events across different patient risk groups.
- Incidence of symptomatic VTE after arthroplasty
- Risk stratification for low, intermediate, and high VTE risk patients
- Impact of prophylaxis strategies on postoperative recovery
Ongoing trials evaluate how tailored anticoagulant protocols affect safety and recovery for individuals undergoing total knee and hip arthroplasty.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Equipe Zorgbedrijven Nederland B.V.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Individualized Thrombosis Prophylaxis with Apixaban, Nadroparin Calcium, and Dabigatran in Patients Undergoing Total Hip or Knee Arthroplasty | Leids Universitair Medisch Centrum (LUMC) | Phase III | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Andexanet Alfa | 1 | Unknown | 2024-10-23 | 2024-10-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.